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Abstract 
Background: As medication non-adherence continues to be a global public health 
problem, the development, evaluation and implementation of interventions to 
address this prevalent problem represent a key priority. Community pharmacists’ 
role is evolving from the dispensing of medications to the provision of professional 
services aiming at improving patient outcomes. Pharmacists have, therefore, the 
potential to deliver interventions to manage medication adherence. Nonetheless, 
there is still a lack of evidence on the effect of community pharmacist-led 
interventions on medication adherence and clinical outcomes. 
Objectives: To explore and evaluate the impact of medication adherence 
interventions undertaken by community pharmacists across different chronic 
diseases. This research aims to provide evidence on the efficacy and effectiveness of 
community pharmacist-led interventions in Australia and Spain on medication 
adherence to interventions and disease-specific outcomes.  
Methods: Multiple methods were applied in this research. Chapter 2 presents a 
systematic review and network meta-analysis, following the PRISMA guidelines, 
comparing long term interventions on the impact on medication adherence across 
different chronic diseases. Chapter 3 describes a retrospective observational study 
evaluating the impact of a real-life practice intervention in Australia provided by 
community pharmacist to patients with chronic medications (rosuvastatin, 
desvenlafaxine, irbesartan). Chapter 4 present a cRCT to evaluate the impact of a 
medication adherence management service in a community pharmacy setting in 
Spain. Chapter 5 describes a sub-analysis of the cRCT including patients with asthma 
and COPD being prescribed inhaled medications. A multilevel regression model was 
used to measure the impact of the medication adherence management service on 
medication adherence and disease-specific clinical outcomes (Chapter 4) and inhaler 
technique (Chapter 5). Chapter 6 presents an effectiveness-implementation hybrid 
design evaluating the clinical impact of the medication adherence management 
service when translated to routine practice during an implementation study. For this 
analysis, patients were classified in three groups: A) those allocated to the 
intervention group during the cRCT and continue during implementation, B) those 
allocated to the control group during the CRCT and continue during implementation, 
and C) new patients in the implementation study. 
Results: Chapter 3 presents the impact of a real-life community pharmacist-led 
intervention in Australia. De-identified data of 2,530,562 patients and 3,328 
Australian community pharmacies from 2014 to 2017 were contained in the 
database. A total of 1,805 pharmacies and 20,335 patients who met the inclusion 
criteria were included in the analysis, with an average age of 67 (SD: 11.76). Three 
months after the intervention was provided, there was an increase from 50.2% (SD: 
30.1) to 66.9% (SD: 29.9) for rosuvastatin, from 50.8% (SD: 30.3) to 68% (SD: 29.3) 
for irbesartan and from 47.3% (SD: 28.4) to 66.3% (SD: 27.3) for desvenlafaxine, in 
adherence rates.  Rates decreased over 12 months to 62.1% (SD: 32.0) (rosuvastatin), 
62.4% (SD: 32.5) (irbesartan) and 58.1% (SD: 31.1) (desvenlafaxine). 
The results of the cRCT are highlighted in Chapter 4. Patients (n=1,186) were 
recruited from 98 pharmacies and 87.5% (n=1,038) completed the six-month study. 
Compared to control patients, patients receiving the intervention had an Odds Ratio 
(OR) of 5.12 of being adherent at the end of the study. ORs for hypertension control, 
asthma control and COPD low clinical impact were 1.22 (95% CI: 0.78-1.91), 1.88 (95% 
CI: 1.05-3.36) and 2.01 (95% CI: 1.07-3.75), respectively, favouring the intervention 
group. For patients using inhaled medications (i.e. sub-analysis of patients suffering 
from asthma or COPD in the cRCT), the odds of improvement of patients with correct 
inhaler technique were 4.57 favouring the intervention group. The impact of the 
medication adherence management service resulted on an improvement on clinical 
outcomes (e.g. medication adherence and disease-specific outcomes) for all patients 
during the implementation study (i.e. routine-practice), with greater improvements 
observed on those patients who have not been exposed to the intervention before 
(groups B and C). 
Conclusion: Community pharmacist-led interventions lead to an improvement in 
medication adherence and disease-specific clinical outcomes. A real-life intervention 
iv 
v 
in Australia resulted in the improvement of adherence after providing the 
intervention with an eventual decline on adherence rates post-intervention, 
highligthling the importance of continuous follow-up. To improve the effectiveness 
of this intervention, factors such as follow-up, fidelity measures and addition of other 
components to the intervention should be considered. These factors were 
considered when developing a medication adherence management service in Spain. 
This intervention resulted in the improvement of medication adherence and disease-
specific outcomes under the cRCT (controlled environment) and the implementation 
study (real practice). The intervention also improved inhaler technique on patients 
suffering from asthma and COPD and contained multiple components (e.g. 
educational, attitudinal, technical), which have been found effective at improving 
medication adherence. The essential role that community pharmacists have in the 
management of medication adherence should be considered in the development of 
future interventions. 
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Preface 
This thesis is presented in fulfilment of the doctoral degree (Doctor of Philosophy) 
requirements of the University of Technology Sydney, Australia. 
The thesis is structured as a PhD by compilation. Seven chapters are presented 
throughout the thesis, including copies of peer-reviewed publications as chapters of 
the manuscript. Spelling varies between US English and British English to meet 
journal requirements for manuscript submission. Andrea J Torres Robles is the 
primary author of each publication. Co-authors contributed to the conception, design 
of the work, data collection, data analysis, interpretation or critical revision of the 
manuscripts.  
Chapter 1 includes the research overview, an overall rationale and the organisation 
and objectives of the thesis. Chapter 2 covers the contextual background of 
medication adherence interventions, including a systematic review and meta-
analysis, highlighting the gaps and opportunities in practice.  
Chapter 3 – 6 present evidence of the impact of community pharmacist-led 
interventions on medication adherence, addressing the specific objectives. Chapter 
3 presents a retrospective analysis of the impact of a real-life intervention provided 
by community pharmacists in Australia. Chapter 4 describes a cRCT to evaluate the 
impact of a community pharmacist-led medication adherence management service 
in Spain, on medication adherence and disease-specific outcomes. Chapter 5 
presents the impact of the intervention described in the cRCT on inhaler technique 
performance for patients with asthma and COPD. Chapter 6 presents the clinical 
effectiveness of the medication adherence management service during its 
implementation in routine-practice settings. Chapter 7 discusses the overall 
research, reflects on the strengths and limitations of the research work and provides 
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